Even though the confirmed PR rate was only 12% in the first 25 evaluable patients (all platinum-resistant patients), the 6-month PFS rate of 56% (14 of 25) met the efficacy criteria, justifying progression to second-stage accrual 6 min read Sigma2 Receptors Even though the confirmed PR rate was only 12% in the first 25 evaluable patients (all platinum-resistant patients), the 6-month PFS rate of 56% (14 of 25) met the efficacy criteria, justifying progression to second-stage accrual cmerp December 12, 2022 Even though the confirmed PR rate was only 12% in the first 25 evaluable patients (all platinum-resistant...Read More